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Abstract
Background: Vulvar squamous cell carcinoma (VSCC) is a rare malignancy of the female genital tract. We aimed to
determine the mucosal high-risk human papillomavirus (HPV)-attributable fraction of VSCCs from Italian women
using multiple markers of viral infections.
Methods: VSCCs and 8 metastatic lymph node samples from 107 Italian women were analyzed by a highly type-
specific multiplex genotyping assay for the presence of DNA from 119 different HPVs. Tissues were further analyzed
for HPV RNA and for upregulation of the cellular protein p16INK4a.
Results: The rate of mucosal HPV-related tumors defined by viral DNA and RNA positivity was low (7.8%). HPV16
was the most prevalent, followed by 53, 56, and 58. Only five (4.9%) p16INK4a-positive tumors were also positive for
both viral DNA and RNA. One (14.3%) metastatic lymph node sample was positive for all three markers. DNA of
cutaneous HPVs was detected in only two VSCCs, i.e. genus beta types 5 and 110.
Conclusion: A small proportion of Italian VSCCs is putatively HPV-related, i.e. positive for both viral DNA and RNA of
the same type, thus reinforcing the importance of HPV vaccination. Moreover, this study suggests that a direct role
of HPV from genus beta and gamma in vulvar carcinogenesis is unlikely.
Keywords: Cancer, Human papillomavirus, Lymph node metastatic tissues, Vulvar squamous cell carcinoma,
Multiple markers of viral infections
Introduction
Vulvar squamous cell carcinoma (VSCC) is a rare tumor
of the female genital tract, accounting for about 5% of all
gynecological malignancies [1, 2]. In North America, the
incidence of VSCC has increased by 0.6% annually in the
past decade [1, 3, 4]. Moreover, tumor nodal recurrence is
typically fatal [1]. The primary treatment approach for
VSCC is surgery, complemented in selected cases by
chemotherapy/radiotherapy [5], with negative psychosex-
ual consequences [1, 6]. VSCC includes two distinct types,
with apparently different etiology: (i) VSCC associated
with infection with mucosal high-risk (HR) human papil-
lomaviruses (HPVs), and (ii) HPV-independent VSCC [7,
8]. HPV-related VSCC is more common in younger
women and is always preceded by a pre-malignant lesion,
i.e. vulvar high-grade squamous intraepithelial lesion
(VHSIL) [9, 10]. HPV-independent VSCC occurs mainly
in older women [1, 11] and arises from a chronic inflam-
matory dermatosis, referred to as lichen sclerosus [12, 13],
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that can evolve into differentiated vulvar intraepithelial
neoplasia (VIN), a precursor lesion of VSCC [14].
Based on a pooled prevalence rate of HPV DNA, 34%
of vulvar cancers have been reported to be attributable
to HPV [15].
Although detection of HR-HPV DNA is a valid testing
approach for the identification of pre-malignant and ma-
lignant cervical lesions, its use for other anatomical sites,
including the vulva, is insufficient proof for viral causal-
ity and can lead to misclassification of the lesion [16,
17]. Therefore, the use of additional markers for active
HR-HPV infections, such as overexpression of the hu-
man cyclin-dependent kinase-4 inhibitor p16INK4a (p16)
or/and detection of viral RNA, may enable more precise
estimation of the proportion of VSCC that may be at-
tributable to HPV, as previously shown in head and neck
cancer [16].
As recently suggested, a useful protocol for the identi-
fication of HPV-related VSCC is the simultaneous detec-
tion of HPV DNA and RNA [16, 17].
The evaluation of p16 protein expression by immuno-
histochemistry (IHC) enables discrimination between
HPV-independent and HPV-related cancers at anatom-
ical sites outside the cervix, including the vulva [17–21].
However, because there are a limited number of studies
evaluating p16 expression in VSCC, the actual reliability
of p16 protein expression as a single marker of onco-
genic HPV infection for this tumor entity is not entirely
known [17, 18, 22, 23]. Detection of both HPV DNA
and p16 overexpression to classify the two different
VSCC subtypes has also been proposed, but for VSCC
this algorithm has not yet been fully validated [17, 18,
21]. However, the detection of viral transcripts as a
marker of biological HPV activity in the lesion tissue, in
addition to HPV DNA and p16 overexpression, may sig-
nificantly improve the classification of truly HPV-
positive VSCC.
A multicenter study using HPV DNA and p16 positiv-
ity as markers has shown that approximately 25% of vul-
var cancers worldwide may be associated with HPV [18].
This study, which included tumor specimens collected
from cancer cases in 39 countries on five continents,
highlighted some variability in HPV positivity in VSCC
in the different geographical regions. However, some
geographical variations in HPV-positive VSCC may be
due simply to the analysis of a relatively low number of
specimens in specific countries. Thus, additional studies
are required in individual countries, where only limited
information on the association between HR-HPV and
VSCC is available.
Regarding HR-HPV-negative VSCC, the involvement
of other infectious agents, including the cutaneous genus
beta and gamma HPV types, has been poorly investi-
gated. Studies have reported the presence of these HPV
types in the anogenital tract [24, 25]. In addition, several
investigations have highlighted the transforming proper-
ties of genus beta and gamma HPV types in various ex-
perimental models [26–28].
In this study, we aimed to determine the HPV-
attributable proportion of VSCC by analyzing HPV
DNA and RNA status, and by determining p16 expres-
sion level, in a large retrospective cohort of VSCC cases
from Italy. In addition, we examined the possible role of
genus beta and/or gamma HPV types in VSCC.
Materials and methods
Sample collection
The Ethics Committee of the Hospital of Turin approved
this study to be in compliance with the Declaration of
Helsinki (reference number 1005). All patients had signed
informed consent at the time of hospital admission. The
inclusion criteria were: invasive vulvar carcinoma (i.e. an
invasive depth > 1mm), squamous cell histological type,
and no prior surgical treatment for vulvar cancer or any
other malignancy (apart from biopsy). The exclusion
criteria were: primary site other than vulva, recurrent tu-
mors, HIV- or hepatitis C virus (HCV)-positive patients,
and non-consenting patients.
Formalin-fixed, paraffin-embedded (FFPE) VSCC samples
obtained from 107 women (mean [±standard deviation (SD)]
age, 73 [11.8] years) collected during 2013–2016 were
retrieved from the archive of the Department of Obstetrics
and Gynecology, University of Turin, Sant’Anna Hospital,
Turin, Italy. According to the International Federation of
Gynecology and Obstetrics (FIGO) classification of vulvar
cancer [29], the VSCCs were in the following stages: IB
(54.2%); II (0.9%); IIIA (19.6%); IIIB (11.2%); IIIC (4.7%); and
IVA (9.3%). The mean tumor diameter was 29mm (SD, 15.8
mm), and 42.1, 45.8, and 12.1% of tumors showed depth of
invasion of < 5mm, 5–12mm, and > 12mm, respectively. Ar-
chived FFPE metastatic lymph node samples (MTS) were also
available from 8 women with VSCC tissue (mean [±SD] age,
69 [16.5] years).
Preparation of paraffin sections and tumor evaluation
Ten sections of 10 μm from each FFPE tissue block were
processed at the Department of Pathology, University of
Turin, Italy. Sections S1 and S10 were used for
hematoxylin and eosin histology, and S2 and S9 were
used for p16 IHC. In addition, S3–S5 and S6–S8 were
collected for DNA and RNA extraction, respectively. To
avoid cross-contamination between different samples,
each time a new case was sectioned, the microtome was
extensively washed with DNA Away (Dutscher,
Brumath, France) and a new microtome blade was used.
Empty paraffin blocks were cut after every 10 cancer
specimens and blindly analyzed. Tumor size/status was
documented by routine pathologic evaluation, in
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accordance with the World Health Organization (WHO)
classification [30].
Nucleic acid extraction
Total DNA was prepared by incubating overnight at 37 °C
three internal FFPE sections (S3–S5) from each VSCC/
MTS tissue in 250 μl of digestion buffer (10mM Tris/HCl
at pH 7.4, 0.5 mg/ml proteinase K, and 0.4% Tween 20).
Then, to inactivate the proteinase K and to separate paraf-
fin from the aqueous phase, samples were incubated at
95 °C for 10min, centrifuged, and chilled on ice [31]. The
aqueous phase was transferred to a new tube.
Total RNA was prepared from tissue sections S6–S8
using the PureLink FFPE Total RNA Isolation Kit (Invitro-
gen, Carlsbad, CA, USA). DNase I (RNase-Free DNase
Set, Qiagen, Hilden, Germany) treatment was carried out
on the RNA purifying columns during sample processing
as previously described [32]. Extracted RNA was eluted in
50 μl of RNase-free water and stored at − 80 °C until use.
HPV DNA detection and genotyping
HPV DNA was detected by E7 type-specific multiplex
genotyping (E7-MPG), which combines multiplex poly-
merase chain reaction (PCR) and hybridization to type-
specific oligonucleotide probes on fluorescent beads
(Luminex Corp., Austin, TX, USA) [33, 34]. E7-MPG
uses HPV type-specific primers targeting the E7 region
of 12 HR-HPVs (HPV16, 18, 31, 33, 35, 39, 45, 51, 52,
56, 58, 59), 7 possible/probable HR (pHR)-HPVs
(HPV26, 53, 66, 68, 70, 73, 82), and two low-risk (LR)
HPVs (HPV6 and 11). Forty-six genus beta HPVs
(HPV5, 8, 9, 12, 14, 15, 17, 19, 20, 21, 22, 23, 24, 25, 36,
37, 38, 47, 49, 75, 76, 80, 92, 93, 96, 98, 99, 100, 104,
105, 107, 110, 111, 113, 115, 118, 120, 122, 124, 143,
145, 150, 151, 152, 159, 174) and 52 genus gamma HPVs
(HPV4, 48, 50, 60, 65, 88, 95, 101, 103, 108, 109, 112,
116, 119, 121, 123, 126, 127, 128, 129, 130, 131, 132,
133, 134, 148, 149, 156, 161, 162, 163, 164, 165, 166,
167, 168, 169, 170, 171, 172, 173, 175, 178, 179, 180,
184, 197, 199, 200, 201, 202, SD2) [35–41] were detected
using the same methodology.
The sensitivity has been evaluated using serial dilu-
tions of DNA from HPV types. This multiplex PCR
protocol is highly sensitive, with the ability to detect
only 10 copies of the viral genome [34, 40].
HPV mRNA analysis
All HPV DNA-positive VSCC/MTS tissues, including
HPV16 and non-HPV16 DNA-positive samples, and a
group of 10 randomly selected HPV DNA-negative tissues
were analyzed for HPV16 E6*I mRNA and, as a control
for tissue and RNA quality, for human UbC mRNA. Tis-
sues that were DNA-positive for HR- and pHR-HPV types
other than HPV16 were also analyzed for E6*I mRNA of
the specific HR- and pHR-HPV types(s) detected. In
addition, tissues that were DNA-positive for LR-HPV6 or
11 were analyzed for the presence of unspliced E6 mRNA
of HPV6 and 11, respectively. RNA detection from FFPE
sections was performed as previously described [32].
Briefly, 1 μl of extracted RNA was subjected to a one-step
reverse transcription PCR protocol with the QuantiTect
Virus Kit (Qiagen, Hilden, Germany) using HPV type-
specific primers to amplify 65–75 bp cDNA sequences
across the E6*I splice sites [32]. The biotinylated strands
of the amplicons were detected by hybridization with
type- and splice site-specific oligonucleotide probes
coupled to fluorescence-labelled Luminex beads (Luminex
Corp., Austin, TX, USA). The E6*I mRNA assays are
available for 20 HR- or pHR-HPV types for which exist-
ence of splice sites was demonstrated [32]. For detection
of unspliced LR-HPV6 and 11 mRNA, primers designed
to amplify a 77 bp amplicon of the full-length HPV6 or 11
E6 gene, and an oligonucleotide probe for detection of
full-length HPV11 E6, were applied.
Samples that were negative in duplicate assays for
HPV E6*I or E6 and for UbC mRNA were considered
RNA-invalid.
p16 immunohistochemistry
Expression of p16 was evaluated manually by IHC in
FFPE sections using the CINtec p16 Histology Kit
(Roche mtm laboratories AG, Mannheim, Germany) ac-
cording to the manufacturer’s instructions and as previ-
ously described [42]. Expression of p16 was evaluated by
IHC in all VSCC and MTS cases. Continuous, diffuse
nuclear and cytoplasmic staining in 70% or more of the
tumor cells was considered p16-positive, and focal stain-
ing or no staining was considered p16-negative. All
slides were evaluated three times by three different eval-
uators (SSP, RW, RR), who were blinded to the clinical
and epidemiological data. The final classification of the
staining was based on the majority consensus.
Results
HPV infection markers in VSCCs
Of 107 VSCC and 8 MTS cases initially selected, five
VSCC cases and one MTS case were excluded due to in-
valid RNA (n = 3) and p16 (n = 2) data, or to the absence
of cancer tissue in the block (n = 1). Thus, a total of 102
VSCC and 7 MTS tissues were included in the analysis.
The 102 VSCC cases had a mean age of 70 years (SD,
12.8 years); FIGO stages were IB (52.9%), II (1%), IIIA
(20.6%), IIIB (10.8%), IIIC (4.9%), and IVA (9.8%). Mean
tumor diameter was 30mm (SD, 15.7mm) and mean
depth of stromal invasion 8mm (SD, 6.3 mm), with 40.2,
47.1 and 12.7% of tumors showing depth of invasion of <
5mm, 5–12mm, and > 12mm, respectively. Furthermore,
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MTS selected from 7 cases were analyzed (mean [±SD]
age, 73.9 [13.5] years).
Table 1 and Supplementary Table S1 show the HPV
DNA, RNA, and p16 detection in VSCC and MTS cases.
Mucosal HPV DNA was detected in 17 of 102 (16.7%)
VSCCs and all 7 MTS cases (100%). HPV16 was the most
prevalent type; it was present in 10 of the 17 HPV DNA-
positive VSCCs (58.8%), followed by HPV6 (2/17, 11.8%),
HPV18 (1/17, 5.9%), HPV53 (1/17, 5.9%), HPV56 (1/17,
5.9%), HPV58 (1/17, 5.9%), and HPV82 (1/17, 5.9%). Only
one multiple infection was detected, containing HPV16,
18, and 56. All MTS cases were positive for mucosal HPV
DNA. Five MTS cases contained a single HPV type, i.e.
HPV16 (n = 1), HPV6 (n = 3), and HPV56 (n = 1). Multiple
HPV infections were detected in two MTS cases; both
were positive for HPV6 and HPV16 (Table 1). Matched
VSCC and MTS cases of three women were positive for
the same HPV DNA, i.e. HPV6 (n = 2) and HPV16 (n = 1).
There was no concordance for the HPV types in the
remaining MTS cases (n = 4) and the corresponding
VSCCs (Supplementary Table S1).
To evaluate the etiological role of the mucosal HPV
detected, all 17 HPV DNA-positive VSCC and all 7 MTS
cases were analyzed for the presence of HR- and pHR-
HPV E6*I and unspliced E6 for LR-HPV (Table 1). All
24 HPV DNA-positive VSCC and MTS cases were ubC
mRNA-positive. Considering both HPV DNA and RNA
positivity, the percentage of HPV-related VSCCs was
7.8% (8/102), i.e. HPV16 (n = 6), HPV53 (n = 1), HPV56
(n = 1), and HPV58 (n = 1). One VSCC case simultan-
eously tested positive for HPV DNA and RNA from
HPV16 and HPV56. Of the 7 mucosal HPV DNA-
positive MTS cases, only one (14.3%) had E6*I mRNA of
the same type (HPV16). None of the HPV6 DNA-
positive cases tested positive for full-length HPV6 E6
mRNA.
Overexpression of the cell-cycle inhibitor p16 is a
well-validated surrogate marker of HPV transformation
in the cervix [43]. We determined the p16 IHC positivity
in all 102 VSCC and 7 MTS cases (Fig. 1). Eleven VSCC
cases were positive for p16 (11/102, 10.8%). Of these,
five were also HPV DNA- and RNA-positive (Table 1).
Thus, when all three markers were considered, the per-
centage of HPV-related VSCC cases dropped from 7.8 to
4.9% (5/102) (Table 1). The remaining p16-positive cases
(n = 6) were HPV DNA-positive and HPV RNA-negative
(n = 2) or HPV DNA-negative and HPV RNA-negative
(n = 2), or were not tested for HPV DNA and RNA (n =
2). Only one MTS case showed p16 overexpression (1/7,
14.3%), and was also positive for HPV16 DNA and RNA.
The corresponding VSCC from the same case was also
positive for all three markers.
The presence of DNA of cutaneous beta and gamma
HPV in cytological samples of the genital tract has been
Table 1 HPV DNA, RNA, and p16 positivity in 102 VSCC and 7 MTS cases
VSCC (N = 102) MTS (N = 7)




Any HPV DNA 17 (16.7) 7 (100.0)
DNA and RNAa 8 (7.8) 1 (14.3)
DNA, RNA, and p16a 5 (4.9) 1 (14.3)
HPV16 single infection DNA 9 (8.8) 1 (14.3)
DNA and RNA 5 (4.9) 0 (0.0)
DNA, RNA, and p16 4 (3.9) 0 (0.0)
Mucosal HPV other than HPV16 single infections DNA 7 (6.9)b 4 (57.1)d
DNA and RNA 2 (2.0)c 0 (0.0)
DNA, RNA, and p16 0 (0.0) 0 (0.0)
Multiple infections DNA 1 (1.0)e 2 (28.6)g
DNA and RNA 1 (1.0)f 1 (14.3)h
DNA, RNA, and p16 1 (1.0) 1 (14.3)
HPV Human papillomavirus, MTS Metastatic lymph node samples, VSCC Vulvar squamous cell carcinoma
aHPV RNA was examined in 17 VSCC and 7 MTS HPV DNA-positive cases and a randomly selected subset of HPV DNA-negative cases (n = 10). p16 expression was
examined in all VSCC (n = 102) and MTS (n = 7) cases
bSingle infections: HPV6 (n = 2), HPV18 (n = 1), HPV53 (n = 1), HPV56 (n = 1), HPV58 (n = 1), HPV82 (n = 1)
cSingle infections: HPV53 (n = 1), HPV58 (n = 1)
dSingle infections: HPV6 (n = 3), HPV56 (n = 1)
eCoinfection: HPV16, HPV18, and HPV56 (n = 1)
fCoinfection: HPV16 and HPV56 (n = 1)
gCoinfection: HPV6 and HPV16 (n = 2)
hSingle infection: HPV16 (n = 1)
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reported [24, 37, 44]. We also determined the presence
of DNA of 46 genus beta and 52 genus gamma HPV
types in all VSCC and MTS cases. Only two VSCC cases
were positive for beta HPV types (i.e. HPV5 and
HPV110), and no gamma HPV types were detected in
the VSCC and MTS cases analyzed.
Discussion
Mucosal HR-HPV types have been clearly associated
with the development of a small subset of VSCC. How-
ever, the contribution of the viral infectious agents ap-
pears to vary in different geographical regions [15]. In
particular, limited information is available for the contri-
bution of HR-HPV to VSCC development in Italy. In
this study, we analyzed a large number of VSCCs col-
lected in a hospital in northern Italy during 2013–2016.
In the first step, we investigated the presence of HPV
DNA in VSCCs by using a sensitive HPV genotyping ap-
proach covering all oncogenic and probably/possibly
oncogenic HPV types. The prevalence of HPV DNA-
positive cases was observed to be nearly 17%. Previous
studies on VSCC reported HPV DNA frequencies ran-
ging from 29 to 45% [17, 18, 21, 45, 46]. However, the
overall results indicate that HPV could have a role in the
development of a proportion of VSCC cases. In agree-
ment with a previous study [17], we observed HPV16 to
be the most common HR-HPV type detected in VSCC.
In addition, viral DNA from HPV18, 53, 56, 58, and 82
was also detected, with low frequency. The LR-HPV type
6 was found to be the second most common viral type
in this study, suggesting that it may be involved, together
with other factors, in VSCC onset or progression [17,
46]. Recently, Faber et al. (2017) reported a prevalence
of 6.8% (19/277) for HPV6 DNA as a single infection in
VIN, and 1.1% (6/527) in VSCC [47].
Because HPV transcriptional activity may reflect its
oncogenic activity, we applied a HPV-type-specific E6*I
mRNA detection method, established for 20 HR- or
pHR-HPV types and validated for use in FFPE tissues, to
evaluate the presence of HPV RNA in HPV DNA-
positive VSCCs. We observed viral RNA in 47.1% (8/17)
of HPV DNA-positive VSCC cases, with HPV16 RNA
showing the highest prevalence. Eight of 102 VSCC
cases (7.8%) were likely to be HPV-driven, i.e. positive
for both HPV DNA and RNA. None of the HPV6 DNA-
positive samples tested positive for HPV RNA. The up-
regulation of p16 has been suggested as a surrogate
marker for oncogenic HR-HPV infections, and p16 IHC
has frequently been used not only to determine and/or
confirm positivity for HPV in various tumors but also to
define HPV-related tumors [19]. Therefore, p16 expres-
sion has also been studied in VSCC before [17, 22, 48,
49]. In the present study, this cellular marker was over-
expressed in approximately 50% of HR-HPV DNA-
positive VSCC cases (7/15). Other series of VSCC stud-
ies previously showed 70–80% of HPV DNA-positive
VSCC cases expressing p16 [17, 46]. However, in our
study, p16 overexpression was observed in the majority
(5/8, 62.5%) of HR-HPV DNA- and RNA-positive
VSCCs. A lower p16 positivity rate in HR-HPV DNA-
negative VSCCs (4/85, 4.7%) and in HR-HPV DNA-
positive and HPV RNA-negative VSCCs (2/7, 28.6%) was
also detected. Overexpression of p16 in HPV DNA-
negative VSCCs may be a consequence of either a muta-
tion of CDKN2A, the gene coding for p16 [50], or the
inactivation of the retinoblastoma protein pRb (e.g. by
mutation), which then leads to upregulation of p16 [51].
Previous reports showed higher concordance between
the HR-HPV transcript expression and p16 overexpres-
sion, ranging from 83 to 90% [17, 21, 49]. The causes of
this discrepancy between our results and those of previ-
ous published studies are unknown.
In this study, we were also able to retrieve MTSs for a
small number of patients with VSCC. Only one case
showed concordance in HPV DNA/RNA positivity and
p16 expression between VSCC and MTS.
The investigation of the presence of HR-HPV E6
mRNA instead of analyzing E6 oncoprotein, which may
be more informative on the oncogenic implications of
HR-HPVs in VSCC development, may be considered a
limitation of this study. However, we focused our atten-
tion on evaluating the expression of the p16 protein,
Fig. 1 p16ink4a immunohistochemistry staining. Negative p16ink4a staining (a), and diffuse nuclear and cytoplasmic p16ink4a staining (b) in VSCC
cases. Magnification X10
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which is considered a surrogate marker for all trans-
forming HR-HPV infections and represents a single tar-
get molecule, different from the E6 proteins with type-
specific polypeptide sequence variability.
Finally, although independent studies have reported that
cutaneous beta and gamma HPV types can be detected in
the genital tract, our study does not provide evidence for
their involvement in the development of VSCC.
Conclusion
We characterized the HPV-independent and HPV-
related VSCCs in a cohort of more than 100 VSCC cases
from Italy. We identified as putative HPV-related tumors
a small proportion of VSCC cases that tested positive for
both HPV DNA and RNA. Our results support the
causative role of HPV in vulvar carcinogenesis in a dis-
tinct subset of cases and highlight the prevalence of
HPV16, thus reinforcing the importance of HPV vaccin-
ation programs.
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